SEC Company Response from FILANA THERAPEUTICS, (FLNA) — May 1, 2020
FILANA THERAPEUTICS, INC.
Date: May 1, 2020 · CIK: 0001069530 · Accession: 0001069530-20-000028
AI Filing Summary & Sentiment
File numbers found in text: 333-237452
Letter
Correspondence
May 1, 2020
VIA EDGAR
Division of Corporation Finance
Office of Life Sciences
United States Securities and Exchange Commission
100 F Street, NE
Washington, D.C. 20549
Attention: Jeffrey Gabor
Re:
Cassava Sciences, Inc.
Registration Statement on Form S-3
File No. 333-237452
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Cassava Sciences, Inc. (the “Registrant”) hereby requests acceleration of effectiveness of its registration statement on Form S-3 (File No. 333-237452) to 4:00 p.m., Eastern Time, on May 5, 2020, or as soon as practicable thereafter.
The Registrant requests that it be notified of such effectiveness by contacting Alfredo B. D. Silva, the Company’s counsel at Morrison & Foerster LLP, at (415) 268-6213 or asilva@mofo.com.
Very truly yours,
Show Raw Text
CORRESP 1 filename1.htm Correspondence May 1, 2020 VIA EDGAR Division of Corporation Finance Office of Life Sciences United States Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Attention: Jeffrey Gabor Re: Cassava Sciences, Inc. Registration Statement on Form S-3 File No. 333-237452 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Cassava Sciences, Inc. (the “Registrant”) hereby requests acceleration of effectiveness of its registration statement on Form S-3 (File No. 333-237452) to 4:00 p.m., Eastern Time, on May 5, 2020, or as soon as practicable thereafter. The Registrant requests that it be notified of such effectiveness by contacting Alfredo B. D. Silva, the Company’s counsel at Morrison & Foerster LLP, at (415) 268-6213 or asilva@mofo.com. Very truly yours, Cassava Sciences, Inc. By: /s/ Remi Barbier Name: Remi Barbier Title: Chief Executive Officer